Clinical Trials Logo

Filter by:
NCT ID: NCT06459778 Recruiting - Infertility, Female Clinical Trials

Piezo-ICSI to Improve the Developmental Potential of Fertilized Oocytes in Aged Infertility Women With Assisted Reproductive Technology

Start date: November 20, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test Piezo-ICSI on improving oocyte fertilization and embryo development in elderly infertile patients undergoing intracytoplasmic sperm injection (ICSI). The main question it aims to answer is whether Piezo-ICSI could improve oocyte fertilization and embryo development. Participants requested ICSI are asked to randomly culture equal numbers of oocyte and embryo with or without Piezo-ICSI. At the time of injection, two or more mature oocytes were split into two groups (i) conventional ICSI and (ii) Piezo-ICSI (50:50 split).

NCT ID: NCT06459427 Not yet recruiting - Clinical trials for Robotic Surgical Procedures

Robot-Assisted Minimally Invasive Surgery for Brainstem Hemorrhage

Start date: July 2025
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to observe the improvements in clinical symptoms and imaging outcomes for brainstem hemorrhage using robot-assisted stereotactic puncture, evaluate the clinical efficacy and safety of this treatment, and explore the development of a high-precision, intelligent, and individualized microsurgical diagnosis and treatment process for brainstem hemorrhage. The main questions it aims to address are: - Establish a multi-center clinical database for brainstem hemorrhage. - Clinically observe and evaluate the intervention effects of robot-assisted stereotactic puncture on brainstem hemorrhage, compare it with the traditional conservative treatment control group, and investigate its efficacy and impact on patient survival, motor evoked potentials, and the degree of neurological deficits. - Optimize the Artificial Intelligence (AI) algorithm-based robotic surgical assistance system, and explore the prediction of preoperative brainstem hematoma stability and hematoma path planning. Participants in the experimental group will: - Undergo robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture - Receive conservative non-surgical treatment. If there is a control group: the researchers will compare the conservative non-surgical treatment group to evaluate the effectiveness of robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture.

NCT ID: NCT06459310 Not yet recruiting - Aging Clinical Trials

Pilot Study on Evaluating the Geroprotective Effect of Metformin

AGE-M
Start date: June 30, 2024
Phase: Phase 2
Study type: Interventional

The objective of this research is to assess the efficacy of oral metformin in mitigating the aging process in middle-aged and elderly males, to pinpoint sensitive indicators of human senescence, and to offer innovative frameworks and scientific insights for pharmaceutical interventions in aging.

NCT ID: NCT06459245 Enrolling by invitation - Clinical trials for Breast Cancer Female

Resistance Training to Prevent Lymphedema After Breast Cancer Surgery Randomized Controlled Study

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

Based on the best evidence, this study intends to construct resistance appropriate for this clinical scenario,The training program was designed in a randomized controlled study for patients with breast cancer after surgery for a period of 3 months,To investigate the effect of resistance training on the grip strength of the affected limb, the range of motion of the shoulder joint of the affected limb, the occurrence of lymphedema of the affected limb, and the quality of life of patients with breast cancer after surgery,To provide theoretical guidance and practical basis for functional rehabilitation management of patients with affected limbs after surgery.

NCT ID: NCT06459167 Not yet recruiting - Emergencies Clinical Trials

Position Intervention to Reduce Hypoxemia in Sedation Patients

Start date: June 20, 2024
Phase: N/A
Study type: Interventional

Hypoxemia was defined as an SpO2 of < 90% for any duration. Failure to treat promptly can lead to hypoxemia, which may increase the risks of arrhythmia, nausea and vomiting, and cognitive dysfunction. Studies have shown that body position has a direct impact on respiratory function. In special environments, including outside the operating room where emergency airway management for critically ill and injured patients is needed, or in areas with limited medical resources like remote areas, adopting simple interventions by changing position to maintain patients' respiratory function can be more economical, convenient and safe.

NCT ID: NCT06459141 Recruiting - Transfusion Clinical Trials

The Effect of Hemodilution on Intraoperative Allogeneic Transfusion (HEAL)

Start date: June 2024
Phase: N/A
Study type: Interventional

The prevention of intraoperative allogenetic blood transfusion has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone tumor surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial, and intraoperative fluid administration strategy is an important confounding factor. The HEAL trial will assess whether ANH will reduce the volume of intraoperative allogeneic red blood cell transfusion when applying goal-directed fluid therapy in patients undergoing bone tumor surgery.

NCT ID: NCT06458972 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Safety, Efficacy, and Compliance of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)

Start date: January 1, 2024
Phase:
Study type: Observational

Systemic lupus erythematosus (SLE) is a highly specific autoimmune disease that involves multiple systems due to abnormal immune activation. It is a classical diffuse connective tissue disease with autoimmune inflammation as its prominent manifestation. B cells are the core of systemic lupus erythematosus (SLE) pathogenesis. B Lymphocyte Stimulator (BLyS, also called BAFF) and A Proliferation-Inducing Ligand (APRIL) are signals for B cell maturation. B Lymphocyte Stimulator (BLyS) participates in promoting the development and maturation of B cells, while A Proliferation-Inducing Ligand (APRIL) participates in promoting the activation of mature B cells and the secretion of antibodies by plasma cells. Telitacicept is composed of the extracellular specific soluble portion of Transmembrane Activator and Calcium-modulating Cyclophilin Ligand (CAML) Interactor (TACI) and the Fragment crystallizable (Fc) segment of human Immunoglobulin G1 (IgG1). It is the only globally approved dual-target biological agent for the treatment of systemic lupus erythematosus (SLE) , blocking B Lymphocyte Stimulator (BLyS) and A Proliferation-Inducing Ligand (APRIL), hindering the development and activation of B cells, and the production of antibodies, comprehensively inhibiting the maturation, proliferation, and differentiation of B cells at different stages. In this study, the investigators will explore the adherence and influencing factors of telitacicept in systemic lupus erythematosus (SLE) patients, its effectiveness, and safety, providing a stronger basis for clinical management of systemic lupus erythematosus (SLE) patients.

NCT ID: NCT06458673 Recruiting - Clinical trials for Multiple Pulmonary Nodules

A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules

Start date: November 1, 2023
Phase:
Study type: Observational [Patient Registry]

Some studies have shown that the model for judging and predicting the growth of sub-solid pulmonary nodules through big data and deep learning can detect nodule growth earlier. Since most of the training data come from large foreign samples, most of the validated data are CT data from a single center or a few centers, and their generalization ability needs to be further verified. In order to better study subsolid pulmonary nodules in the lungs in China, we plan to conduct a prospective, multicenter, non-interventional observational cohort study.

NCT ID: NCT06458595 Not yet recruiting - Clinical trials for Age-related Macular Degeneration

Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Start date: June 28, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.

NCT ID: NCT06458413 Recruiting - Clinical trials for Breast Cancer Recurrent

Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

Start date: June 5, 2024
Phase: Phase 2
Study type: Interventional

This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients. This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.